L
ower limb arterial thrombosis causes a sudden decrease in limb perfusion that threatens the viability of the limb. 1 The incidence of acute peripheral arterial occlusion is ≈1.5 cases per 10 000 person-years. 2 Risk factors include atherosclerosis, atrial fibrillation, smoking, hypertension, diabetes mellitus, myocardial infarction, aneurysmal disease in the aorta or lower limb, and deep venous thrombosis. 3, 4 It has been established previously that deep venous thrombosis in the lower limb and pulmonary embolism may be presenting symptoms of cancer 5 and are associated with a poor cancer prognosis. 6 However, whether arterial thromboembolism of the lower limb also can represent prodromal symptoms of occult cancer and worsen cancer prognosis has never been investigated. Despite similarities, 7 the mechanisms of thrombus formation are fundamentally different in the venous versus arterial systems, 8 preventing extrapolation of results from studies of venous thromboembolism.
A recent study examined the association between chronic intermittent claudication and cancer 9 and reported increased long-term risk, presumably driven by smoking as a strong risk factor for both diseases. An acute thrombotic event such as lower limb arterial thrombosis may be linked to cancer through mechanisms other than shared risk factors. First, an undiagnosed, yet active, cancer may induce a hypercoagulable and prothrombotic state, 10 increasing the risk of arterial thrombosis. Second, occult cancers may compress vessel walls of adjacent arteries supplying the lower limb. Hence, arterial thrombotic episodes in the lower limb may precede symptoms of malignancy. This would merit increased clinical attention and possible opportunistic screening for cancers in such patients.
We therefore examined the risk of cancer overall and of site-specific cancers after a diagnosis of lower limb arterial thrombosis, compared with cancer risk in the general population. Moreover, we assessed the prognostic impact of previous lower limb arterial thrombosis on all-cause mortality after common cancers.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Such disclosure would conflict with the regulations for the use of Danish healthcare data.
Setting
We conducted this nationwide population-based cohort study in Denmark, which has 5.7 million inhabitants. The Danish National Health Service provides tax-supported health care, guaranteeing free and equal access to primary and hospital care. 11 Complete and valid linkage of all registries at the individual level is possible in Denmark using the unique central personal registry number assigned to each Danish citizen at birth and to residents on immigration.
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Patients With Lower Limb Arterial Thrombosis
Using the Danish National Patient Registry, 12 we identified all hospital inpatients and outpatients diagnosed with firsttime lower limb arterial thrombosis between January 1, 1994, and November 30, 2013. Each hospital discharge and outpatient visit is recorded in the registry with 1 primary diagnosis and up to 19 secondary diagnoses classified according to the International Classification of Diseases, Eighth Revision through 1993 and International Classification of Diseases, Tenth Revision thereafter. We used both primary and secondary diagnoses to identify patients with lower limb arterial thrombosis. To ensure that cases of lower limb arterial thrombosis and cancer outcomes both were incident, we excluded patients with a history of lower limb arterial thrombosis or cancer at any time before the hospital contact for lower limb arterial thrombosis.
Outcomes
We used the Danish Cancer Registry to identify all cancer diagnoses after the diagnosis of lower limb arterial thrombosis. Diagnoses in the Danish Cancer Registry have high validity, with 95% to 98% completeness and accuracy of recorded diagnoses. 13 The registry contains detailed data, including
Clinical Perspective
What Is New?
• Venous thromboembolism can be a presenting symptom of cancer and an adverse prognostic factor for patients with cancer; however, it remains unknown whether a thrombus in the arterial system of the lower limb is also a marker of increased cancer risk and poor cancer outcome.
• In a nationwide population-based cohort including 6600 patients with lower limb arterial thrombosis, the risk of any cancer was increased in comparison with the general population, especially during the first 6 months of follow-up.
• Lower limb arterial thrombosis was also an adverse prognostic factor for mortality in common cancers.
What Are the Clinical Implications?
• To assess lower limb arterial thrombosis as a prognostic factor for all-cause mortality in patients with cancer, we used the Danish Cancer Registry to construct a matched comparison cohort of patients who had cancer without lower limb arterial thrombosis. For each patient with lower limb arterial thrombosis with cancer, we sampled up to 5 patients with cancer from the general population using risk-set sampling, matched on age at cancer diagnosis (5-year intervals), year of cancer diagnosis (5-year intervals), sex, cancer type, and cancer stage. We included cancer types that were common and had high mortality (ie, colon, lung, urinary bladder, breast, and prostate cancer). Diagnostic codes used in the study are presented in Tables I through IV in the online-only Data Supplement.
Statistical Analysis
We characterized the patients with lower limb arterial thrombosis according to sex, age group (0-29, 30-49, 50-69, ≥70 years), individual comorbidities including risk factors for lower limb arterial thrombosis, and level of comorbidity according to Charlson Comorbidity Index scores. 14 We followed patients from the hospital contact date for lower limb arterial thrombosis until the occurrence of a cancer diagnosis, emigration, death, or November 30, 2013, whichever came first. Absolute cancer risks were calculated at 6 months, 1 year, 5 years, 10 years, and end of follow-up (19 years and 11 months) by using the cumulative incidence risk function, accounting for death as competing risk. 15, 16 Incidence rates were calculated using the number of events divided by risk time. Associated 95% confidence intervals (CIs) were derived by using a normal approximation (Wald interval), 17 assuming a Poisson distribution.
As a measure of relative risk, standardized incidence ratios were calculated as the observed number of cancers relative to the expected number, based on national incidence rates by sex, age in 5-year intervals, and calendar period in 5-year intervals. 18 Associated 95% CIs were derived using the Byar approximation, assuming that the observed number of cases in a specific category followed a Poisson distribution. We used exact 95% CIs when the observed number of cancers was <10. 19 Multiplying the number of person-years of observation by these national incidence rates yielded the number of cancer cases that would be expected if patients with lower limb arterial thrombosis had the same risk of cancer as the general population. In addition, we computed hazard ratios (HRs) and corresponding 95% CIs using a stratified Cox proportional hazards regression model, comparing patients with lower limb arterial thrombosis with individuals from the general population, matched on age, sex, and calendar year in a 1:20 ratio. We characterized matched comparators according to sex, age group, and comorbidity.
We stratified our analyses by follow-up period (0-6, 7-12, and >12 months), sex, age group (0-29, 30-49, 50-69, and ≥70 years), calendar period (1994-2003 and 2004-2013) , risk factors for lower limb arterial thrombosis (atrial fibrillation, myocardial infarction, aneurysmal disease in the aorta or lower limb, deep venous thrombosis, and intermittent arterial claudication), and primary versus secondary lower limb arterial thrombosis diagnoses. Assuming that cancers diagnosed during the first year of follow-up were present at the time of lower limb arterial thrombosis diagnosis, we computed the number of patients needed to screen at the time of diagnosis to detect 1 excess cancer as the reciprocal of the excess risk. 20 To increase the positive predictive value of the registry diagnosis of lower limb arterial thrombosis, we restricted a subanalysis to patients who received computed tomography angiography, magnetic resonance angiography, conventional angiography, or relevant surgery on the femoral artery (including thrombectomy, embolectomy, and endarterectomy) during their hospital contact for lower limb arterial thrombosis. These restricted analyses included only patients diagnosed with lower limb arterial thrombosis after the year 2000, when registration of the procedure and surgery codes was initiated.
Because the use of vitamin K antagonists in patients with venous thromboembolism has been associated with lower risk of cancer, 21 and a recent report has supported such antineoplastic effect, 22 we stratified our analyses by 90 days preadmission use of aspirin, clopidogrel, vitamin K antagonists, and direct oral anticoagulants.
We performed 3 additional analyses to assess the robustness of our results. First, to isolate the association with lower limb arterial thrombosis caused by local thrombosis, we restricted an analysis to patients without prior intermittent claudication and excluded cases caused by emboli. Second, to differentiate between cancer risk associated with lower limb arterial thrombosis and intermittent claudication, we matched patients with lower limb arterial thrombosis to patients with intermittent claudication from the general population in a 1:10 ratio, by age, sex, and calendar year. Third, to avoid any detection bias occurring during the first phase following lower limb arterial thrombosis, we performed a landmark analysis, excluding the initial 30 days of follow-up.
In the survival analysis, we used the Kaplan-Meier estimator to graphically illustrate survival for the 5 most common cancers (combined and separately), and computed survival estimates at 6 months, 1 year, 5 years, 10 years, and 20 years (end of follow-up). In addition, we computed corresponding HRs controlled for matching factors and adjusted for the individual comorbidities listed in Table 1 , using a stratified Cox regression analysis. Proportional hazards were assessed using log-log plots and found valid in all Cox regression analyses.
All statistical analyses were conducted by using SAS, version 9.4 (SAS Institute). The study was approved by the Danish Data Protection Agency, record number 1-16-02-1-08. In Denmark, registry-based research does not require approval from an ethics committee or informed consent from patients.
RESULTS
We identified 6600 patients with lower limb arterial thrombosis (53% male, Table 1 ). The majority of patients with lower limb arterial thrombosis were ≥70 years (53%), had a primary diagnosis of this condition (81%), and had a moderate (48%) or severe (17%) level of comorbidity. Median follow-up time for patients with lower limb arterial thrombosis was 2.7 years (25-75th percentiles, 0.3-6.8 years). For the 131 989 matched comparators, we observed a lower prevalence
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of comorbidity and a median follow-up time of 6.7 years (25-75th percentiles, 2.5-10.0 years). We observed 772 incident cancers during 20 years of follow-up, corresponding to a standardized incidence ratio for any cancer of 1.35 (95% CI, 1.25-1.45). The 6-month cumulative risk for any cancer was 2.5% (95% CI, 2.1%-2.9%), increasing to 3.5% (3.0%-3.9%) after 1 year, and 17.9% (95% CI, 16.5%-19.3%) after 20 years (end of follow-up). The 6-month standardized incidence ratio for any cancer was 3.28 (95% CI, 2.79-3.82). This standardized incidence ratio remained elevated during 7 to 12 months of follow-up (1.42; 95% CI, 1.09-1.83), and beyond 12 months of follow-up (1.14; 95% CI, 1.05-1.24) ( Table 2 ). These standardized incidence ratios agreed with the HRs comparing patients with lower limb arterial thrombosis with a matched general population comparison cohort (Table 3) .
During 0 to 365 days of follow-up, patients with lower limb arterial thrombosis were at particularly increased risk of the following site-specific cancers: cancers of the lung (standardized incidence ratio, 5.26; 95% CI, 3.92-6.92) and other smoking-related cancers (cancers of the pancreas [standardized incidence ratio, 7.76; 95% CI, 4.52-12.43] and urinary bladder [standardized incidence ratio, 2.71; 95% CI, 1.48-4.55]). Among other common cancers, including cancers of the colon, breast, prostate, and nonmelanoma skin cancer, only the risk of colon and breast cancer was ≈2-fold increased in comparison with the risk in the general population (Table 4) . Risks of all site-specific cancers are presented in Table V in the online-only Data Supplement. Corresponding HRs controlled for matching factors consistently agreed with standardized incidence ratio estimates across follow-up periods and strata in all analyses.
Based on 131 excess cancers (224 observed cancers minus 93 expected cancers) detected in the lower limb arterial thrombosis cohort during 4815 person-years of follow-up the first year after diagnosis, the number of patients with lower limb arterial thrombosis needed to screen to detect 1 excess cancer per year was 37 (95% CI, 30.1-47.3) for any cancer.
Additional Analyses
In stratified analyses, the results were generally in agreement in strata of sex and type of lower limb arterial thrombosis diagnosis (Table VI in the online-only Data Supplement). Most cancers were diagnosed in patients >50 years, and the excess risk of any cancer during the first year was more pronounced in patients aged 50 to 69 years (standardized incidence ratio, 3.36; 95% CI, 2.71-4.11) than in those >70 years of age (standardized incidence ratio, 2.02; 95% CI, 1.68-2.40). The risk of any cancer during the first year was similar for patients diagnosed with lower limb arterial thrombosis from 1994 to 2003 (standardized incidence ratio, 2.44; 95% CI, 1.99-2.96) and from 2004 to 2013 (standardized incidence ratio, 2.40; 95% CI, 1.99-2.87). In analyses restricted to patients who received relevant imaging and surgery of the lower limb during their hospital contact for lower limb arterial thrombosis, results remained similar to those In the analysis restricted to patients with a local thrombosis, the results were similar to the main results in all follow-up periods (Table XI in the online-only Data Supplement). The association also remained when we matched patients with lower limb arterial thrombosis to patients with intermittent claudication, although the association was present only during the first 6 months (Table XII in the online-only Data Supplement). In the landmark analysis excluding the first 30 days of followup, the association persisted throughout the remainder of follow-up, albeit with slightly attenuated strength (Table XIII in the online-only Data Supplement).
Survival Analyses
In the survival analyses, we examined 323 patients with colon cancer, 888 patients with lung cancer, 289 patients with urinary bladder cancer, 298 patients with breast cancer, and 365 patients with prostate cancer. Characteristics of patients who had cancer with prior lower limb arterial thrombosis and their matched comparators are presented in Table XIV in the online-only Data Supplement. In general, patients who had cancer with prior lower limb arterial thrombosis had a higher prevalence of comorbidities. Cancer survival overall was lower in patients with prior lower limb arterial thrombosis (Figure) . For individual cancers, survival also was lower in patients who had cancer with prior lower limb arterial thrombosis, except for patients with prostate cancer ( Figure I in the online-only Data Supplement and Table XV in the online-only Data Supplement).
Consistent with these findings, lower limb arterial thrombosis was an adverse prognostic factor for all-cause mortality following a diagnosis of colon, lung, urinary bladder, or breast cancer, but not prostate cancer (Table  XVI in 
DISCUSSION
In this nationwide population-based cohort study, patients with lower limb arterial thrombosis had a higher 
ORIGINAL RESEARCH ARTICLE
risk of a subsequent diagnosis of cancer than the general population, mainly driven by smoking-related cancers. The cancer risk was increased primarily during the first 6 months and remained moderately increased after 1 year of follow-up. It is interesting to note that both absolute and relative cancer risks, and the temporality of the association during follow-up, as well, were comparable to risks previously reported for venous thromboembolism. 5 Our results were consistent in analyses comparing cancer risk in patients with lower limb arterial thrombosis with the entire general population and with matched individuals from the general population, whereas the association with cancer was moderately attenuated in the comparison with matched individuals with intermittent claudication. Lower limb arterial thrombosis also was an adverse prognostic factor for all-cause mortality after colon, lung, urinary bladder, and breast cancer, but not after prostate cancer.
No previous study has examined the association between lower limb arterial thrombosis and cancer. A cohort study of patients with intermittent claudication found a weaker association with short-term cancer (3-month standardized incidence ratio, 2.2), but comparable risk during the ensuing 4 to 12 months of follow-up (standardized incidence ratio≈1.4), which persisted at this level beyond 1 year of follow-up as opposed to our results. 9 The mechanism behind our findings may involve occult cancers that cause lower limb arterial thrombosis before the cancer itself becomes clinically overt. Hence, reverse causation presumably underlies the observed associations, implying that lower limb arterial thrombosis presents as part of a paraneoplastic phenomenon. Lower limb arterial thrombosis is a painful condition with acute onset and requires prompt diagnostic workup and treatment, which in turn may reveal an underlying cancer. The finding that the risk of cancer more than halved after 6 months indicates that some cancers were occult and merely disclosed in the course of lower limb arterial thrombosis.
An occult cancer can cause lower limb arterial thrombosis in several ways. Embolization from the occult cancer itself or from complicating atrial fibrillation 23, 24 may cause an arterial thrombosis in the lower limb. 4 Evidence also suggests that many cancers can cause a hypercoagulable and prothrombotic state, 10 which may increase the risk of arterial thrombosis. Prothrombotic factors in cancer include the ability of tumor cells to produce and secrete procoagulant substances and to physically interact with blood cells including platelets. 10 Other mechanisms of thrombus promotion in malignancy include the generation of acute-phase reactants and inflammation, paraproteinemia, and compression of adjacent vascular walls, 10 Malignancies associated with lower limb arterial thrombosis included cancers of the anus, anal canal, retroperitoneum, and peritoneum. The close proximity of these cancer sites to arteries supplying the lower extremities may cause compression and destruction of the vessel wall and subsequent thrombosis or peripheral embolization. The risk of leukemia also was increased and may relate to associated leukostasis, 25 plasma hyperviscosity, 26 and hypercoagulability, 10,27 which may facilitate the formation of arterial thrombi. It is interesting to note that we found a moderate attenuation of cancer risk in users of both antithrombotics and anticoagulants. Although our results were only borderline significant, previous studies support an anticarcinogenic effect of warfarin, 22 possibly mediated through blockade of tumorigenesis (independent of anticoagulation) via inhibition of GAS6-AXL signaling. 28 The increased all-cause mortality in patients with common cancers and previous lower limb arterial thrombosis was unlikely to be driven by a heavier comorbidity burden among these patients, because we adjusted for individual comorbidities listed in Table 1 and because all-cause mortality was not affected in patients who had prostate cancer with previous lower limb arterial thrombosis despite their similarly increased comorbidity burden. Several issues should be considered when interpreting our results. The main strength of our study is its population-based design with complete follow-up, limiting the risk of selection bias arising from selective inclusion of specific hospitals, health insurance systems, or income levels. 11 As well, cancer diagnoses have high accuracy and completeness in the Danish Cancer Registry. 13 Heightened diagnostic efforts and the clinical manifestations of occult cancer may in part explain the increased short-term risk. However, the increased risk was remarkably persistent many years after lower limb arterial thrombosis and when excluding the first 30 days of follow-up. Therefore, detection bias should not be prominent. Even in the few years immediately following lower limb arterial thrombosis, detection bias seems unlikely. Such bias would imply a compensatory deficit after the initial period of increased cancer risk, a pattern that was not observed in our data. Finally, lower limb arterial thrombosis and cancer may be driven by shared risk factors that cause lower limb arterial thrombosis before clinically detectable cancer. This mechanism may in part drive the moderate, but consistently increased, long-term risk of cancer after lower limb arterial thrombosis. Specifically, smoking is a strong risk factor for peripheral artery disease 3 and may in part underlie the increased long-term risk of cancers of the mouth, larynx, lung, urinary bladder, and pancreas. 
Cardiovascular diagnoses have high quality in the Danish National Patient Registry 29 and the diagnosis of lower limb arterial thrombosis is rarely undetected or misclassified because of its acute onset, specific symptoms, and severe course. However, the recorded diagnoses of lower limb arterial thrombosis may have been misclassified in a few cases. Such misclassification would likely be nondifferential (ie, not related to the outcomes), and hence lead to an underestimation of the strength of the associations. 30 Moreover, our results remained robust when we restricted our analysis to patients who underwent relevant imaging and surgery.
In conclusion, lower limb arterial thrombosis was a marker of increased risk of cancer, in particular in the short term and most pronounced for smoking-related cancers. In addition, lower limb arterial thrombosis was an adverse prognostic factor for all-cause mortality in patients with colon, lung, urinary bladder, and breast cancer, but not prostate cancer. The potential to herald a clinically silent, but preexisting, cancer merits increased attention to symptoms or signs pointing to a potential cancer when patients present with lower limb arterial thrombosis. It remains unknown whether patients with lower limb arterial thrombosis may accrue prognostic benefit from a formal screening program to detect cancers at an earlier stage. Still, based on our findings, opportunistic screening focused on cancerrelated symptoms and signs during diagnostic workup for lower limb arterial thrombosis seems prudent.
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